Chemotherapy-induced taste alteration and quality of life survey in patients with breast cancer

Chemotherapy-Induced Taste alteRation and qUality of life Survey in patients with breast cancer - CITRUS study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053013

Enrollment

100

Registered

2023-12-07

Start date

2023-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Breast cancer patients planned to receive Doxorubicin+Cyclophosphamide(ddAC, Tri-weekly AC),Docetaxel+Cyclophosphamide,or Pembrolizumab+Carboplatin+Paclitaxel as perioparative chemoteherapy.

Exclusion criteria

Exclusion criteria: 1. Patients who have received chemotherapy during the last three years. 2. Patients unable to take oral intake. 3. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2,3 or 4 4. Patients deemed by the investigator to be inappropriate for the study.

Design outcomes

Primary

Measure	Time frame
Taste alteration measured by CiTAS and NRS	—

Secondary

Measure	Time frame
QOL change measured by EORCT-QLQ-30	—

Countries

Japan

Contacts

Public ContactKaede Baba

National Cancer Center Hospital East Department of pharmacy

kababa@east.ncc.go.jp0471331111

Outcome results